- Home
- DSGN vs ELDN Comparison
DSGN vs ELDN Comparison
Compare DSGN & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- ELDN
- Stock Information
- Founded
- DSGN 2017
- ELDN 2004
- Country
- DSGN United States
- ELDN United States
- Employees
- DSGN N/A
- ELDN N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- DSGN Health Care
- ELDN Health Care
- Exchange
- DSGN Nasdaq
- ELDN Nasdaq
- Market Cap
- DSGN 208.9M
- ELDN 178.4M
- IPO Year
- DSGN 2021
- ELDN N/A
- Fundamental
- Price
- DSGN $3.87
- ELDN $3.15
- Analyst Decision
- DSGN Hold
- ELDN Strong Buy
- Analyst Count
- DSGN 1
- ELDN 2
- Target Price
- DSGN $4.00
- ELDN $12.50
- AVG Volume (30 Days)
- DSGN 92.9K
- ELDN 664.8K
- Earning Date
- DSGN 08-12-2025
- ELDN 08-18-2025
- Dividend Yield
- DSGN N/A
- ELDN N/A
- EPS Growth
- DSGN N/A
- ELDN N/A
- EPS
- DSGN N/A
- ELDN N/A
- Revenue
- DSGN N/A
- ELDN N/A
- Revenue This Year
- DSGN N/A
- ELDN N/A
- Revenue Next Year
- DSGN N/A
- ELDN N/A
- P/E Ratio
- DSGN N/A
- ELDN N/A
- Revenue Growth
- DSGN N/A
- ELDN N/A
- 52 Week Low
- DSGN $2.60
- ELDN $2.38
- 52 Week High
- DSGN $7.77
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- DSGN 47.12
- ELDN 43.14
- Support Level
- DSGN $3.89
- ELDN $2.90
- Resistance Level
- DSGN $4.19
- ELDN $3.27
- Average True Range (ATR)
- DSGN 0.23
- ELDN 0.29
- MACD
- DSGN -0.02
- ELDN -0.09
- Stochastic Oscillator
- DSGN 16.18
- ELDN 21.10
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.